Xconomy: Flagship Ventures News, Articles and Opinions

“flagship-ventures” Archives

Entry	Author	Date	Location
Quentis Nets $48M For Cancer Drugs, Building Buzz For NY Bio Startups	Ben Fidler	02/27/18	New York
In Biggest Biotech IPO of 2017, Denali Raises $248M for Neuro Drugs	Frank Vinluan	12/08/17	San Francisco
Bio Roundup: RNAi’s Big Day, CAR-T For Kids, Drugs From Fungi & More	Ben Fidler	09/22/17	National
HubSpot Buys Dating App, Joule Winds Down, & More Boston Tech News	Jeff Engel	09/07/17	Boston
Stalled or Rising Momentum? New York Wrestles With Its Biotech Future	Ben Fidler	05/10/17	New York
Seventh Sense Gets Initial FDA Clearance for Simple Blood-Draw Device	Jeff Engel	02/23/17	Boston
Varmus, Sato on Steering De Blasio’s $500M Plan to Grow NY Biotech	Ben Fidler	12/30/16	New York
Bio Roundup: NY Rises, Prez Inks Cures, Ophthotech Crashes & More	Alex Lash	12/16/16	National
Flagship Pioneers New Name, $285M ‘Special Opportunities’ Fund	Frank Vinluan	12/15/16	Boston
NY Bio Surge Continues as De Blasio Unveils $500M, 10-Year Life Sci Plan	Ben Fidler	12/13/16	New York
Seventh Sense Biosystems Sucks In $10M for Simple Blood-Draw Device	Jeff Engel	11/18/16	Boston
New York Institutions, VCs Team up to Build Drug Discovery “Bridge”	Ben Fidler	10/31/16	New York
New Rockefeller Prez Takes Stock of “Wildly Underdeveloped” NY Bio Scene	Ben Fidler	09/27/16	New York
Eleven Bio Buys Viventia, Rebrands as Cancer Drug Developer	Ben Fidler	09/21/16	Boston
Seeking to Join Editas, Intellia, CRISPR Tx Makes Long Awaited IPO Push	Ben Fidler	09/12/16	Boston
Filing: Moderna Blowing Past Record $450M Round With New $600M Raise	Ben Fidler	08/29/16	Boston
3D Printing Startup NVBots Nabs Cash & New CEO, Moves Into Metal	Jeff Engel	08/18/16	Boston
In a Microbiome Setback, Seres Drug Fails in Phase 2, Shares Crushed	Ben Fidler	07/29/16	Boston
With $40M Bid, Pfizer Set to Buy, And Close, Bankrupt Bind Tx	Ben Fidler	07/27/16	Boston
Indigo’s Microbial Tech for Crops Lands $100M to Fight Plant Stresses	Frank Vinluan	07/21/16	Boston
With Bugs As Drugs, Evelo CEO Plans Immune, Cancer Trials in 2017	Alex Lash	07/12/16	Boston
Pfizer Might Buy Bind Therapeutics From Bankruptcy for $20M	David Holley	07/06/16	Boston
Syros Cuts Price But Bags $50M in IPO to Fuel Cancer Drug Trials	Ben Fidler	06/29/16	Boston
Alexandria Sets up Incubator, $25M Seed Fund For NY Bio Startups	Ben Fidler	06/08/16	New York
Pronutria Rebrands as Axcella Health, Forms “Nutrition” Subsidiary	Ben Fidler	06/07/16	Boston
Syros Files For IPO to Push “Gene Control” Drugs Through First Trials	Ben Fidler	06/06/16	Boston
Retooled Selecta Bio Takes Crossover Cash to IPO Queue	Ben Fidler	05/24/16	Boston
CarGurus CEO on Profitable Tech Startups, and Why Uber Is Road Kill	Jeff Engel	05/16/16	Boston
Amid Leadership Changes, NY Biotech Braces For its “Pivotal Moment”	Ben Fidler	05/12/16	New York
Pressured by a Lender, Bind Files for Bankruptcy	Ben Fidler	05/02/16	Boston
Page 1 of 17	next page »